Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. develops medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions for healthcare providers. News about GEHC commonly covers its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions businesses, including MR, CT, molecular imaging, women’s health, X-ray, ultrasound, image-guided solutions, and enterprise imaging.
Company updates also address quarterly results, orders and backlog, operational changes, acquisitions such as Intelerad, and product or collaboration announcements. Recurring themes include next-generation SIGNA MR systems, helium-free MR technology, bkActiv intraoperative ultrasound integration, AI-powered mammography tools, and the mangaciclanol MRI contrast-agent pipeline.
GE HealthCare (GEHC) is highlighting nuclear medicine innovations at SNMMI 2026, focusing on expanding access, AI-enabled workflows and radiopharmaceutical advances.
Key offerings include Omni Legend PET/CT, StarGuide SPECT/CT, MIM AI software, MINItrace Magni cyclotron, and imaging agents such as Flyrcado, DaTscan, Cerianna and Vizamyl, supporting scalable, precision care.
GE HealthCare (Nasdaq: GEHC) will use the ESTRO 2026 Congress in Stockholm to showcase AI-enabled solutions across radiation therapy, theranostics, and image-guided interventions.
Highlights include the Intelligent Radiation Therapy (iRT) platform, new iRT for Theranostics, advanced MIM oncology software, and BK Medical real-time surgical imaging technologies.
GE HealthCare (Nasdaq: GEHC) is showcasing next-generation SIGNA MR technologies at ISMRM 2026, highlighting AI-powered workflow, helium-free 1.5T systems and advanced 3T scanners. New tools such as SIGNA One, SIGNA Bolt, SIGNA Sprint with Freelium, SIGNA Studio and the investigational MAGNUS prototype aim to accelerate MR research, enhance collaboration and translate innovation into clinical practice.
GE HealthCare (Nasdaq: GEHC) reported Q1 2026 results: revenues $5.13B (+7.4% YoY; organic +2.9%), book-to-bill 1.07 and backlog $21.8B. Net income was $389M (diluted EPS $0.85); Adjusted EPS $0.99. Cash from operations $290M; free cash flow $112M. Company closed the $2.3B Intelerad acquisition and reaffirmed organic revenue guidance while reducing profit and free cash flow outlook due to inflation, tariffs and a resolved PDx supplier issue.
GE HealthCare (Nasdaq: GEHC) reorganized operations and executive leadership effective April 29, 2026 to streamline execution, accelerate innovation, and drive growth. The company created Advanced Imaging Solutions (AIS) — a combined Imaging and Advanced Visualization Solutions segment sized at $14.6 billion — led by Phil Rackliffe.
Catherine Estrampes becomes Chief Commercial and Growth Officer to lead a new Global Markets region (all markets except China). Roland Rott will leave the company. GE HealthCare will recast financials to reflect the new segment structure in its Q2 2026 SEC filings.
GE HealthCare (Nasdaq: GEHC) said members of its management team will present at two investor conferences in May and June 2026. Bank of America Health Care Conference presentation is May 12, 2026 at 10:40 am PT / 1:40 pm ET. Jefferies Global Healthcare Conference presentation is June 3, 2026 at 9:20 am ET. Webcasts will be available on the company investor website on the listed dates.
GE HealthCare (Nasdaq: GEHC) announced the first patient was dosed in the international Phase 2/3 LUMINA trial of its manganese-based MRI contrast agent, mangaciclanol, on April 23, 2026.
Mangaciclanol has FDA Fast Track designation for adults and pediatric patients aged 2+, showed tolerability in Phase 1, and demonstrates comparable relaxivity to gadobutrol. The company highlights potential supply and environmental advantages versus gadolinium agents. Mangaciclanol remains investigational and is not approved for clinical use.
GE HealthCare (Nasdaq: GEHC) expanded its collaboration with DeepHealth (RadNet subsidiary) to commercially extend DeepHealth’s AI-powered Breast Suite internationally and integrate new applications with GE’s Pristina Via mammography systems. The deal adds ProFound Pro, Safeguard Review, and cloud-first workflow tools to scale AI-enabled breast cancer screening and second‑reader workflows.
GE HealthCare (NYSE:GEHC) announced a commercial digital integration linking the bkActiv intraoperative ultrasound system with the Medtronic Stealth AXiS surgical navigation system to provide real-time imaging during cranial procedures.
The integration supports plug-and-play visualization to help assess anatomy changes such as brain shift and complements planning, navigation and robotics; the Stealth AXiS has U.S. FDA clearance for cranial procedures.
GE HealthCare (Nasdaq: GEHC) will release first quarter 2026 financial results before market open on Wednesday, April 29, 2026.
The GE HealthCare management team will host a live conference call and webcast at 8:30 a.m. ET the same day. Materials and a replay will be posted on the company investor website.